Glenmark Pharmaceuticals Limited
GLENMARK · Pharma · NSE
₹2,241
Current Market Price
Fair Value (DCF)
₹1,324
Margin of Safety
-40.9%
Updated just now
YieldIQ Score
56/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
41%
ROE
11.8%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.63 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.9%
Return on capital employed
EV / EBITDA
25.8×
Enterprise multiple
Debt / EBITDA
0.5×
Leverage vs earnings
Interest Coverage
7.8×
EBIT covers interest
Current Ratio
1.56×
Short-term liquidity
Asset Turnover
0.85×
Revenue per ₹ of assets
Revenue CAGR (3Y)
7.6%
3-year revenue growth
Revenue CAGR (5Y)
8.1%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,240.9
Bear case
₹794.16
MoS -182.2%
Base case
₹1,323.84
MoS -69.3%
Bull case
₹1,803.85
MoS -24.2%
Ratio Trends
GLENMARK · last 8 annual periods
ROE
11.8%
ROCE
18.5%
Operating Margin
—
Debt / Equity
0.28×
PE
34.7×
EV / EBITDA
10.1×
Historical Financials
GLENMARK · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹10.9K Cr | ₹12.3K Cr | ₹13.0K Cr | ₹11.8K Cr | ₹13.1K Cr | +4.7% |
| EBITDA | — | ₹2226 Cr | ₹1200 Cr | ₹1183 Cr | ₹2092 Cr | -1.5% |
| EBIT | ₹1736 Cr | ₹1739 Cr | ₹1218 Cr | ₹552 Cr | — | -24.9% |
| PAT | ₹970 Cr | ₹994 Cr | ₹377 Cr | ₹-1434 Cr | ₹1047 Cr | +1.9% |
| EPS (diluted) | ₹34.38 | ₹33.37 | ₹10.53 | ₹-67.30 | — | — |
| CFO | ₹1131 Cr | ₹1109 Cr | ₹625 Cr | ₹-265 Cr | ₹-828 Cr | — |
| CapEx | — | — | — | — | ₹-750 Cr | — |
| FCF | — | — | — | — | ₹-1577 Cr | — |
| Total Assets | — | ₹17.1K Cr | ₹19.4K Cr | ₹14.4K Cr | ₹16.0K Cr | -1.5% |
| Total Debt | — | — | ₹496 Cr | ₹991 Cr | ₹2473 Cr | +49.5% |
| Shareholders' Equity | — | — | ₹9474 Cr | ₹7848 Cr | ₹8849 Cr | -1.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
GLENMARK vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| LAURUSLABS LAURUSLABS | — | — | Pending | 7.8% | — |
| ALKEM ALKEM | — | — | Pending | 17.4% | — |
| ABBOTINDIA ABBOTINDIA | — | — | Pending | 33.4% | — |
| AUROPHARMA AUROPHARMA | — | — | Pending | 10.7% | — |
| MANKIND Mankind Pharma Limited | -40.3% | 47 | Above Fair Value | 13.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
11 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹15.00/sh
Last payout
2025-10-03
₹2.50
Peak payout
₹2.50
Trailing yield
0.22%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Glenmark Pharmaceuticals Limited (GLENMARK.NS) trades at 2240.90 vs a model fair value of 1323.84, a gap of -40.9%. Piotroski F-score: 7/...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of GLENMARK →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for GLENMARK →
Compare
Head-to-head with peers
Compare GLENMARK side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse GLENMARKNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.